WebSep 9, 2024 · L iquid biopsy company Grail has filed for a $100 million initial public offering, according to SEC documents. The company, which has raised about $2 billion from … WebSep 9, 2024 · Grail was spun out of Illumina, a maker of DNA-sequencing machines, in 2015, and it has gone on to raise more than $2 billion in financing from a range of …
$1.6 billion liquid biopsy player Grail files IPO, revealing 2024 ...
WebSep 21, 2024 · Dive Brief: Illumina has agreed to acquire Grail in an $8 billion deal that could establish the sequencing giant as a leading player in the growing race to use blood-based tests known as liquid biopsies to catch cancers early.; Grail spun out of Illumina in 2016 and raised $2 billion to back its work. Long-rumored to be considering an initial … WebSep 9, 2024 · GRAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. impact of illegal sugar imports in malawi
GRAIL Company Profile: Acquisition & Investors PitchBook
WebJul 8, 2024 · Back in 2024, Mainz-based BioNTech limped onto Nasdaq with a smaller-than-expected IPO. Now, with its Pfizer-partnered mRNA-based SARS-CoV-2 vaccine on track to reap $26 billion this year,... WebSep 14, 2024 · Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). This move precedes the company’s anticipated 2024 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic … WebSep 9, 2024 · Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals. The Illumina spinout expects to launch the product, Galleri, as a lab developed test, or LDT, in ... impact of ict on privacy